Clinical Trials
10 trialsNCT07322263 2026-04-17
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
University of Iowa
Phase 2 Recruiting
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT06632951 2025-08-11
LIVIGNO-3
AbbVie
Phase 2 Active not recruiting
NCT03737123 2023-09-13
Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT01780545 2022-07-11
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT00880334 2018-09-18
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03209206 2017-12-22
The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence
Seoul National University Hospital
Phase 2 Unknown
NCT00479089 2015-11-02
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01071928 2015-08-19
Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT01907308 2014-04-29
Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
University of Colorado, Denver
Phase 2 Withdrawn